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Abstract
Background: Traditionally standard treatment for patients with early stage endometrial cancer (EC) is
total abdominal hysterectomy and bilateral salpingo oophorectomy (TAH+BSO) with or without lymph
node dissection through a vertical midline incision. While TAH is an accepted effective treatment, it is
highly invasive, visibly scarring and associated with morbidity. An alternative treatment is the same
operation by laparoscopy. Though in several studies total laparoscopic hysterectomy (TLH+ BSO) seems
a safe and feasible alternative approach in early stage endometrial cancer patients, there are no randomized
data available yet. Furthermore, a randomized controlled trial with surgeons trained in laparoscopy is
warranted in order to implement this technique in a safe manner. The aim of this study is to compare the
treatment related morbidity, cost-effectiveness and quality of life in early stage endometrial cancer patients
treated by laparoscopy versus the standard open approach.
Methods: A multi centre randomized clinical phase 3 trial, including 5 university hospitals and 15 regional
hospitals in the Netherlands. Only gynecologists trained in performing a TLH are allowed to participate.
Inclusion criteria: Patients with a clinical stage I endometrioid adenocarcinoma or complex atypical
hyperplasia are randomized in a 2:1 allocation to receive TLH or TAH. The main outcome measure is the
rate of major complications, as assessed by an independent clinical review board. In total, 275 patients are
required to have 80% power at α-0.05 to detect a significant difference of 15% complication rate.
Secondary outcome measures are 1) costs and cost-effectiveness, 2) minor complications, and 3) quality
of life. All data from this multi center study are reported using case record forms. Data regarding quality
of life, pain, body Image, sexuality and additional homecare are assessed with self reported questionnaires.
Discussion: A randomized multi center study in early stage endometrial cancer patients with inclusion
criteria for patients and surgeons is designed and ongoing. Results will be presented at the end of 2009.
Trial Registration: Dutch trial register number NTR821.
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Background
Endometrial cancer is the third most common cancer in
women in Western countries, accounting for 6–9% of
their cancers, with a peak incidence at the age of 55–65
year. Endometrial cancer is a disease of the elderly and
90% of patients are over 50 years of age. The incidence
increases in obese women and 70% of the patients have a
high body mass index (BMI >25) and 50% have co-mor-
bidity such as diabetes and cardiovascular disease. A total
of 75% of the patients are diagnosed with stage I disease.
Traditionally standard treatment for patients with early
stage endometrial cancer (EC) is total abdominal hyster-
ectomy and bilateral salpingo oophorectomy (TAH+BSO)
with or without lymph node dissection through a vertical
midline incision. While TAH is an accepted effective treat-
ment, it is highly invasive, visibly scarring and associated
with adverse events such as blood loss and wound prob-
lems [1,2]. Morbidity of laparotomy in case of endome-
trial cancer can be substantial due to frequent obesity and
co-morbidity in this patient group and hospital stay is
usually at least one week [1]. A good alternative approach
for patients with early stage disease is by laparoscopy.
Laparoscopy in early stage endometrial cancer is a mini-
mal invasive technique compared to the standard
approach by laparotomy. In several retrospective and pro-
spective studies it has been shown that the laparoscopic
approach is an effective and safe alternative to the open
procedure. Most of these studies show a significant reduc-
tion in treatment related morbidity, with shorter hospital
stay, less pain and quicker return to activities in daily life
with the laparoscopic approach compared to laparotomy
[1-10]. The advantages of the laparoscopic approach seem
to be even more pronounced in obese [2] and elderly
patients [10,11] due to reduced complications and a
shorter hospital stay. However, the only randomized con-
trolled trial comparing the laparoscopic approach with
the open approach was in benign disease [12]. This study
is in a different group of patients (young, healthy) than
the study population of the here proposed study i.e. eld-
erly women with endometrial cancer. It is known that
complications occur more frequently during the initial
learning curve of this procedure and some authors suggest
a quantity control (i.e. > 25 TLH procedures) for surgeons
before participating in studies. [12]
Arguments often mentioned hampering the implementa-
tion of level three laparoscopic procedures are the high
preoperative costs and the long learning curve. However,
despite the fact that peroperative costs are higher for lapar-
oscopy due to expensive disposables, it might be that the
overall costs will be finely balanced between both proce-
dures due to reduction of morbidity and shorter hospital
stay [13,14].
Although randomized studies on this issue are not availa-
ble yet, studies in which endometrial cancer patients are
treated show similar rates and patterns of recurrence.
Patients who underwent a TLH+BSO have similar recur-
rence rates when compared to TAH+BSO, as reported in a
retrospective mono-centre study [3] and in two prospec-
tive mono-center studies [6,15]. In view of these data we
proposed a randomized controlled clinical trial in which
total laparoscopic hysterectomy performed by trained sur-
geons is compared to total abdominal hysterectomy in
patients with early stage endometrial cancer.
Methods
Aims&design
The aim of this study is to compare treatment related mor-
bidity, cost-effectiveness and quality of life in early stage
endometrial cancer treated by laparoscopy (TLH+BSO) or
laparotomy (TAH+BSO).
We hypothesize that laparoscopy will result in less treat-
ment-related morbidity in patients treated for early stage
endometrial cancer in a cost-effective manner. The study
will also provide insight on whether the laparoscopic
approach will improve quality of life as compared to the
standard abdominal approach. The proposed research
concerns a multi-center prospective randomized clinical
phase 3 trial (including at least 15 centers) comparing
major complication rate in patients with early stage
endometrial cancer, randomized to surgical treatment by
laparotomy (TAH+BSO) or laparoscopy (TLH+BSO).
Eligibility criteria
Inclusion criteria patients
Early stage endometrial cancer patients (endometrioid
adenocarcinoma grade 1 or 2, clinically stage I disease,
negative endocervical curettage), after signed written
informed consent, age 18 years and older are eligible for
this trial.
Exclusion criteria patients
Exclusion criteria: other histological types than endome-
trioid adenocarcinoma of the endometrium, clinically
advanced disease (stage II to IV), uterine size larger than
conform 10 weeks gestation and cardio pulmonary contra
indications for laparoscopy.
Patient recruitment and consent
Eligible patients are identified and counseled by the gyne-
cological staff of participating hospitals. Before entry into
the study the gynecologist explains to potential subjects
the aims, methods, reasonably anticipated benefits and
potential hazards of the study. Before study entry, on all
patients an endocervical curettage is performed to make
sure that the patient has clinical stage I disease and the cer-
vix is not involved.BMC Cancer 2009, 9:23 http://www.biomedcentral.com/1471-2407/9/23
Page 3 of 7
(page number not for citation purposes)
Subjects are informed that their participation is voluntary
and that they may withdraw consent to participate at any
time during the study. In every center an independent
medical doctor is available for more detailed information
both for patients and colleagues if required. After suffi-
cient information, written informed consent has to be
obtained. The consent form must be signed before per-
formance of any study-related activity. Patients who
decide not to participate in this study are treated accord-
ing to standard treatment protocol (TAH+BSO). Patients
undergo routine physical examination and blood tests
prior to the operation in either treatment arm, which is
part of the standard procedure before surgery.
Randomization and collection of baseline data
The patients to be enrolled in this trial are allocated to the
TAH or TLH arm by computer randomization. For rand-
omization, blocks of x patients are created such that bal-
ance is enforced within each block, stratified per center.
Randomization is 2:1 for intervention to provide more
exposure to data on the new laparoscopic procedure. We
also expect a better enrolment in the study if the patients
have a twofold chance of being allocated to the laparo-
scopic group as the reduced morbidity seems to be sub-
stantial. At study entry, all woman have baseline
demographic, past gynecologic and medical history
recorded in a case record form (CRF). After randomiza-
tion, but prior to surgical treatment, patients are asked to
fill in a questionnaire, consisting items regarding: quality
of life (SF-36, EQ-5D), pain (VAS), Body Image Scale
(BIS), sexuality (SAQ) and a questionnaire on additional
homecare. (see figure 1)
At local centers, data collection is the responsibility of the
local participating gynecologist and research nurses. The
Assessment schedule Figure 1
Assessment schedule.BMC Cancer 2009, 9:23 http://www.biomedcentral.com/1471-2407/9/23
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data collected in this study are coded and processed with
adequate precautions to ensure patient confidentiality.
Interventions
In this trial, the standard surgical approach TAH +BSO
(table 1) is compared to the investigative surgical proce-
dure TLH+BSO (table 2).
Follow-up
Outcomes are assessed pre-operatively, after 6 weeks, and
after 3 and 6 months, being the moments of routine con-
trol assessments and be registered on a case record form
(CRF) by the treating physician and checked by the
research nurse (status review) (see figure 1). Costs are
assessed by a cost assessment (CRF and patient question-
naire). The doctor registers costs on a CRF related to the
use of operation materials (disposables), operating time,
duration of hospital stay, and treatment of complications.
All adverse events are followed until they have abated, or
until a stable situation has been reached.
Data regarding quality of life (SF-36, EQ-5D), pain (VAS),
Body Image Scale (BIS), sexuality (SAQ) and additional
homecare are assessed with help of self reported question-
naires 6 weeks, 3 and 6 months after the operation (see
figure 1).
Monitoring
Pre start monitoring
To minimize complications due to inexperience, all inex-
perienced general gynecologists are trained by a visiting
gynecologist with experience in laparoscopy until suffi-
cient laparoscopic skills are reached, before study entry.
Only gynecologists who reached sufficient scores (≥ 28
points) on OSATS in performing two independent TLH
procedures are allowed to participate in the study. The
study coordinator facilitates centers in order to get
approval of the medical ethical committee. As the study is
set in a national research consortium, allied research
nurses are responsible for collecting data, monitoring of
the study and promote the study at the local centers.
A kick off meeting is held by the study coordinator in
every participating center. During this meeting the con-
tent and inclusion procedure of the study is explained.
On site monitoring
During the study period, frequent contact and assistance
of the coordination center is enabled by regular telephone
calls and visits to all local centers. Furthermore, every
three months newsletters by email are send to the centers
in order to inform the gynecologists about study progress
and bring new items under their attention.
Publicity of the study is realized by means of presenta-
tions held on national and international congresses.
Table 1: Surgical treatment protocol for a TAH, total abdominal hysterectomy
Preoperatively thrombosis prophylaxis is given
Preoperative antibiotic is given at least 15 min before skin incision;
Positioning of the patient in lithotomy position.
Vertical midline incision
Abdominal washing for cytology
Bipolar coagulation or sealing of the round ligament, cutting with monopolar scissors. Opening of the peritoneum of the bladder and the pelvic 
sidewall.
Bipolar coagulation or sealing of the infundibulopelvic ligament, cutting with monopolar scissors
Preparation of the bladder off the vagina
Skeletting the uterine vessels, coagulation or sealing of the vessels, after identification of the ureter.
Coagulation or sealing and cutting of the sacrouterine ligaments.
Taking out the uterus. Closing of the vaginal cuff by abdominal stitching.
Mass closure of sheath, skin closure.BMC Cancer 2009, 9:23 http://www.biomedcentral.com/1471-2407/9/23
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Thereby, the study protocol and other related study docu-
ments are available online. http://www.studies-obsgyn.nl/
home/page.asp?page_id=418.
Case record forms, checked by the research nurse of con-
cerned center and self reported patient questionnaires are
send to the Trial Coordination Center (TCC) of the coor-
dinating center. The TCC takes care of entry and validating
data of case record forms and importing patient question-
naires. In case of discrepancies or inaccuracies found in
the case record forms, queries are send to the centers in
question. Final monitoring will be done by the study
coordinator by visiting randomly selected centers and
checking a part of the case record forms once again.
Study parameters/endpoints
Main study parameter/endpoint
Our primary endpoint is: major complication rate. The
following major complications are registered: injuries of
bowel, bladder, ureter, vessel, nerves; thrombo-embolic
events such as DVT (Deep Venous Thrombosis) or pulmo-
nary embolism; haematoma requiring surgical interven-
tion; hemorrhage requiring transfusion and/or surgical
intervention; wound dehiscence requiring surgical inter-
vention or re-admission; wound infections including vag-
inal vault abscess, requiring surgical intervention and/or
prolonged hospital stay and/or readmission and/or treat-
ment; other major complications.
The severity of a complication is scored according to the
Common Terminology Criteria CTCAE version 3.0. An
independent Complication Review Board of three experi-
enced clinicians is asked to assess and judge all recorded
complications and differentiate between major and minor
complications, blinded to treatment arm. This Complica-
tion Review Board decides also if the complication is
related to the operative procedure, as expressed by the fol-
lowing statements: not related, unlikely related, possibly
related, probably related or definitely related. http://
ctep.cancer.gov/protocolDevelopment/electronic_applications/
docs/newadverse_2006.pdf
Secondary study parameters/endpoints
1) Cost effectiveness
2) Minor complications. Outcomes are assessed by ana-
lyzing the CRF. An independent clinical review panel dif-
ferentiates between major and minor complications,
blinded for treatment arm and also assess whether the
complication is related to the operative procedure.
3) Quality of life (SF-36 and EUROQOL), sexual function-
ing (Sexual Activity Questionnaire), Body Image Scale
(BIS) and pain (Visual Analogue Scale).
Premature termination of the study
The study will be terminated prematurely if the disadvan-
tages of participation may be significantly greater than
Table 2: Surgical treatment protocol for a TLH, total laparoscopic hysterectomy
Preoperatively thrombosis prophylaxis is given
Preoperative antibiotic is given at least 15 min before skin incision;
Positioning of the patient in lithotomy position.
Insufflation of CO2 and placing of the troicarts (4).
Abdominal washing for cytology.
Bipolar coagulation or sealing of the round ligament, cutting with monopolar scissors. Opening of the peritoneum of the bladder and the pelvic 
sidewall.
Bipolar coagulation or sealing of the infundibulopelvic ligament, cutting with monopolar scissors.
Placing the vaginal tube (the Mc Cartney tube). Preparation of the bladder off the vagina.
Skeletting the uterine vessels, coagulation or sealing of the vessels, after identification of the ureter.
Coagulation or sealing and cutting of the sacrouterine ligaments.
Cutting the vaginal wall on the rim of the vaginal tube. Keeping the ureter in sight.
Taking out the uterus. Closing of the vaginal cuff by abdominal or vaginal stitching.BMC Cancer 2009, 9:23 http://www.biomedcentral.com/1471-2407/9/23
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was foreseen in the research proposal. All complications
are assessed and recorded by an independent clinical
review panel. This panel assesses if the complications
occurring in the TLH group do exceed in amount or sever-
ity the complications occurring in the standard of care
(TAH) group. If so, the study will be terminated.
Statistical analysis
Sample size
Sample size estimates are based on the ability of the study
to detect changes in the primary outcome measure, rate of
major complications. In this study, we choose for an
unbalanced randomization (2(TLH+BSO):1(TAH+BSO)).
Group sample sizes of 161 and 81 achieve 80% power to
detect a difference of 0.15 between the null hypothesis
that the major complication rate is 25% in both the TAH
+ BSO and the TLH + BSO group and the alternative
hypothesis that we will observe a complication rate of
25% in the TAH + BSO group and of 10% in the TLH +
BSO group, using a two-sided Chi-square test with conti-
nuity correction and with a significance level of 0.05.
Assuming a drop-out percentage of 10%, 275 patients are
needed.
The assumptions regarding these expected complication
rates are based on the complication rates reported in (ret-
rospective) studies comparing TAH with TLH. In addition,
this is supported by the major complication rate of 9.26%
that we found during the learning curve in our pilot study.
The drop-out percentage of 10% can be expected when
patients, after randomization, are unhappy with their
allocated treatment and choose to end their participation
in the study or due to incomplete or lost data.
Descriptive statistics
Primary endpoints will be analyzed according to the
intention-to-treat principle.
Descriptive statistics for QOL (SF-36, EQ-5D, VAS, BIS,
SAQ) and a questionnaire on additional homecare) will
be calculated for each randomization group at each assess-
ment. Similarly, descriptive statistics will also be calcu-
lated for other outcomes, such as pain scores, and
analgesic consumption, etc. Continuous variables will be
assessed for normality and equality of variances between
groups. Discrete variables (e.g. presence/absence of post-
operative infection) will be summarized by frequencies/
proportions. For continuous variables, analysis of vari-
ance and/or regression will be used, where appropriate. If
assumptions for these tests are violated, alternative non-
parametric tests will be used. Difference between groups
with respect to discrete variables will be evaluated by
using chi-squared tests.
Economic analysis
In the economic evaluation the costs of both interven-
tions will be compared. The economic evaluation will be
conducted from a societal perspective including direct
medical and direct non-medical costs. Relevant cost com-
ponents that will be taken into account are costs of the
laparotomy and laparoscopy, like costs of operating time
and use of disposables. In addition, hospital stay, re-inter-
ventions for post-operative morbidity and operation-
related medication will be assessed. In case of conversion
from TLH to TAH the costs for both procedures will be
added to the costs in the TLH group. Home care, consist-
ing of both professional care as well as informal care will
be assessed as well. Because most women are aged 55 and
older, productivity losses will not be included in the eco-
nomic evaluation.
Cost components will be valued according to standard
Dutch guidelines for economic evaluation (CVZ 2004).
Actual costs will be estimated for the laparotomy and
laparoscopy and informal care will be valued by using
shadow prices.
A case record form will be used to gather medical costs. A
patient questionnaire will be used to collect information
on additional home care. Since no differences regarding
recurrence rate are expected at any time between the two
study arms, a time horizon of six months is considered to
be sufficient for evaluation of morbidity and costs. As a
consequence, discounting will not be applied. A sensitiv-
ity analysis will be conducted to estimate the impact of
variation of major cost elements.
Ethics
The study is conducted according to the principles of the
Declaration of Helsinki and in accordance with the Medi-
cal Research Involving Human Subjects Act (WMO).
The protocol is registered in the clinical Dutch trial regis-
ter number NTR821.
Discussion and conclusion
While the standard abdominal hysterectomy for early
stage endometrial cancer is an effective and accepted treat-
ment in patients with early stage endometrial cancer, it is
highly invasive and associated with serious adverse
events. From retrospective or non-randomized trials can
be concluded that laparoscopic hysterectomy seems a safe
and feasible treatment especially in patients with early
stage endometrial cancer.
GOG-LAP2, a randomized controlled trial in which the
effectiveness of a laparoscopic assisted vaginal hysterec-
tomy with BSO and lymphadenectomy in early stage
endometrial cancer is compared to the open procedure,BMC Cancer 2009, 9:23 http://www.biomedcentral.com/1471-2407/9/23
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has been completed. A major problem in the GOG-LAP2
study is that inexperienced gynecologists in laparoscopic
surgery are allowed to participate and no quality control
for the laparoscopists or the laparoscopic procedure is
performed. Recently, a randomized multi center trial com-
paring the laparoscopic with the open approach in early
stage endometrial cancer called the LACE trial, has been
started in Australia. These studies however, are not appli-
cable to the European situation, because in these studies
patients are mostly treated by a hysterectomy and BSO
combined with a pelvic and para aortic lymphadenec-
tomy. In Europe, a lymphadenectomy is not standard
treatment for patients with early stage endometrial cancer.
Moreover, early stage endometrial cancer patients in our
proposed study only undergo a hysterectomy with BSO
and most of these procedures are performed in general
hospitals by general gynecologists.
Therefore, a randomized multi center trial with on-site
monitoring containing inclusion criteria for patients as
well as for surgeons is designed to provide evidence on
short term outcome between laparoscopy and laparotomy
in patients with early stage endometrial cancer. Results
will be presented at the end of 2009.
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